Currently out of the existing stock ratings of Karl Chalabala, 9 are a BUY (90%), 1 are a HOLD (10%).

Karl Chalabala

Work Performance Price Targets & Ratings Chart

Analyst Karl Chalabala, carries an average stock price target met ratio of 16.67% that have a potential upside of 13.23% achieved within 455 days. Previously, Karl Chalabala worked at UBS, STIFEL, CANACCORD.

Karl Chalabala’s has documented 18 price targets and ratings displayed on 6 stocks. The coverage was on Energy, Healthcare sectors.

Most recent stock forecast was given on FOLD, Amicus Therapeutics at 10-May-2024.

Wall Street Analyst Karl Chalabala

Analyst best performing recommendations are on EQT (EQT).

Average potential price target upside

EQT EQT MR Montage Resources FOLD Amicus Therapeutics CHK Chesapeake Energy Corp AR Antero Resources Corp EXE Expand Energy

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 01-Apr-2025

$68

$15.55 (29.65%)

$72

Hold Since 22-May-2025

$54

$1.55 (2.96%)

$63

Buy Since 19-Oct-2022

$73

$20.55 (39.18%)

$75

17 days ago
(29-Sep-2026)

12/22 (54.55%)

$24.12 (49.35%)

379

Buy Since 06-Dec-2024

$68

$15.55 (29.65%)

$67

23 days ago
(23-Sep-2026)

10/14 (71.43%)

$16.94 (33.18%)

281

Buy Since 15-Apr-2025

$71

$18.55 (35.37%)

$72

29 days ago
(17-Sep-2026)

7/13 (53.85%)

$20.65 (41.01%)

124

Show more analysts

Please expand the browser size to see the chart

✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?